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Abstract: Human plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor with a
metastable active conformation. Under physiological conditions, half of the inhibitor transitions to
a latent state within 1–2 h. The interaction between PAI-1 and the plasma protein vitronectin
prolongs this active lifespan by ~50%. Previously, our group demonstrated that PAI-1 binds to
resins using immobilized metal affinity chromatography (Day, U.S. Pat. 7,015,021 B2, March 21,
2006). In this study, the effect of these metals on function and stability was investigated by
measuring the rate of the transition from the active to latent conformation. All metals tested
showed effects on stability, with the majority falling into one of two types depending on their
effects. The first type of metal, which includes magnesium, calcium and manganese, invoked a
slight stabilization of the active conformation of PAI-1. A second category of metals, including
cobalt, nickel and copper, showed the opposite effects and a unique vitronectin-dependent
modulation of PAI-1 stability. This second group of metals significantly destabilized PAI-1, although
the addition of vitronectin in conjunction with these metals resulted in a marked stabilization and
slower conversion to the latent conformation. In the presence of copper and vitronectin, the half-
life of active PAI-1 was extended to 3 h, compared to a half-life of only ~30 min with copper alone.
Nickel had the largest effect, reducing the half-life to ~5 min. Together, these data demonstrate a
heretofore-unknown role for metals in modulating PAI-1 stability.
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Introduction
Plasminogen activator inhibitor type 1 (PAI-1) is the
primary regulator of the two serine proteases, tis-
sue-type (tPA) and urokinase-type (uPA) plasmino-
gen activator, that initiate fibrinolysis and pericellu-
lar proteolysis.1–6 PAI-1 inhibits tPA and uPA in a
suicidal fashion typical of a serine protease inhibitor
(serpin).7–9 The reactive center loop (RCL) in PAI-1
mimics the peptide substrate of the protease and is
cleaved; however, the acyl intermediate formed
between the protease and the RCL is long lived
because of a conformational change that occurs
within the serpin, effectively inactivating the prote-
ase.10 The availability of the RCL is, therefore, key
to serpin activity.
PAI-1 spontaneously switches from an active to
latent form when the uncleaved RCL is translocated
to the interior central beta sheet in a conformational
change analogous to that occurring after protease
cleavage of the RCL.11 The half-life (t1/2) of the
active conformation of human PAI-1 has been deter-
mined on several occasions by different groups, with
widely varying results that range from 1.5 h to
over a day. When measured at 37C and pH 7.4, the
resulting t1/2 is typically 1–2 h, depending on buffer
conditions.12–21 Because the inhibitory function of
PAI-1 is tied to the active conformation, the transi-
tion to the latent form is a mechanism for regulating
the antiprotease activity and constraining it to a
limited timeframe. Association with the plasma pro-
tein vitronectin increases the t1/2 of PAI-1 by
50%.12,13,15,17,21 This is a high affinity interaction
with a Kd between 0.1 and 1 nM.
22–27 Most of the
active PAI-1 in plasma is bound to vitronectin.28
Some among our group previously showed that
recombinant wild-type PAI-1 binds to immobilized
metal chromatography (IMAC) columns that have
been charged with transition metals.29 However,
beyond use as a convenient purification strategy, the
relevance of these interactions has not been investi-
gated. In this study, the effect of the period 2 and 3
alkaline earth metals (magnesium and calcium) and
several period 4 transition metals (manganese, iron,
cobalt, nickel, and copper) on the stability of PAI-1
has been evaluated. Tests for the effects of metals in
combination with vitronectin on PAI-1 activity were
also pursued. These results point to a novel and
unanticipated role for transition metals in regulation
of PAI-1 structure and function.
Results
Relative affinity of PAI-1 for immobilized
transition metals
In work that has been previously disclosed for a US
patent,29 we demonstrated that the stable 14-1b mu-
tant form of PAI-1 binds to a variety of metals on
IMAC columns that can be exploited for purification
of human PAI-1. A sample elution profile of the
stable 14-1b mutant PAI-1 purification on a nickel-
charged HiTrapTM chelating HP column is shown in
Figure 1, Panel A. Bound PAI-1 elutes from the col-
umn upon application of an imidazole gradient,
detected as a relatively pure protein in fractions C
and D analyzed by SDS-PAGE, as shown in the
inset. Adequate purification, with only minor con-
taminating bands, was also observed on columns
charged with Zn2þ, Cu2þ, and Co2þ, whereas PAI-1
binding to a Mn2þ-charged column was incomplete.
Figure 1, Panel B, shows the imidazole elution range
for PAI-1 binding to the various immobilized metals,
with Ni2þ exhibiting the most binding of PAI-1 and
requiring higher imidazole concentrations for elu-
tion. Thus, using the IMAC approach, more PAI-1
from crude lysates binds to the Group 9–12 metals
(cobalt, nickel, copper, and zinc) than the Group 7
metal, manganese. These results suggest tighter
binding to the transition metals.
Metals affect the stability of PAI-1, both in the
absence and presence of vitronectin
Because of the coordination chemistry of the IMAC
resin, protein binding to the metal ligand occurs via
contributions from a small number of amino acid
functional groups in the protein that contribute to
coordination of the metal; thus, it is not clear from
IMAC alone whether an intrinsic metal binding site
with a full coordination sphere is present in a bound
protein. Thus, although the IMAC results suggested
specific binding, the presence of an intrinsic metal-
binding site in PAI-1 required additional investiga-
tion. First, to further evaluate metal effects on the
structural and functional properties of PAI-1, activ-
ity assays were pursued. The effect of metals on the
half-life for conversion of PAI-1 from the active to
latent conformation (t1/2) in isolation or in the pres-
ence of added vitronectin was measured. Active PAI-
1 was quantified by measuring the level to which
PAI-1 inhibits tPA as a function of time; over the
time course, as PAI-1 relaxes to the latent conforma-
tion, less inhibition of tPA is observed. To embark on
studies to evaluate the effects of metals on PAI-1
function and stability, we first established that met-
als did not interfere with the protease activity of
tPA (data not shown). Furthermore, because metal
chloride was used as the metal source and chloride
has been shown to affect PAI-1 stability,11 NaCl was
used as a chloride control. For all of the metals
tested, the kinetic data fit well to a single exponen-
tial [Fig. 2(a,b)], directly yielding klat, the rate con-
stant for the conversion of active PAI-1 to the latent
conformation. Half-lives calculated from klat for
active PAI-1 in the presence and absence of vitronec-
tin are shown in Figure 2(c) and summarized in Ta-
ble I. Experiments with copper required a different
buffer without BSA to avoid background
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sequestration of copper via the Biuret reaction (see
Methods). Data testing effects of copper on PAI-1 ac-
tivity in the presence and absence of vitronectin are
given in Table II.
All of the metals tested influence PAI-1 stability,
although some effects were modest while others are
quite substantial (Tables I and II and Fig. 2). These
metal effects fall primarily into one of two types.
Type I includes magnesium, calcium, and manga-
Figure 1. PAI-1 binding to immobilized transition metals in
IMAC. In panel A, the stable PAI-1 mutant 14-1b30 from an
overexpressed E. coli lysate was loaded onto a HiTrapTM
chelating HP column charged with nickel, washed with 50
mM NaH2PO4 and 100 mM NaCl pH 6.6, and then eluted
with a linear imidazole gradient. Absorbance at 280 nm was
monitored during the wash and gradient showing elution of
two peaks. Samples of these peaks were collected at
points A through D in the chromatogram, and the fractions
were separated by SDS-PAGE (inset) in the lanes labeled
accordingly. The gel indicated that PAI-1 eluted in the
second peak (fractions C and D). A similar approach was
taken with manganese, cobalt, copper, and zinc
immobilized to the matrix. Panel B shows the concentration
range of imidazole needed to elute PAI-1 from the given
metal resulting in relative affinity information. It should be
noted that the majority of the PAI-1 protein did not bind to
the column charged with manganese.
Figure 2. Kinetic assay showing modulation of PAI-1
stability by metals and vitronectin. Panel A is a semi-log
plot showing a single exponential fit to the loss of PAI-1
inhibitory activity in the presence of MgCl2 or NiCl2
compared to PAI-1 alone. Panel B shows a semi-log plot
with a similar fit; however, in this case PAI-1 plus
vitronectin and MgCl2 or NiCl2 is compared to PAI-1 plus
vitronectin without addition of metals. Panel C gives the t1/2
for PAI-1 with or without vitronectin in the presence and
absence of all metals used in the initial screen (data from
Table I). All kinetic data were determined in buffer
containing 1% BSA and represent the mean and standard
error for three separate experiments (see Methods).
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nese. When compared to the t1/2 of PAI-1 controls
measured in NaCl, each of these Type I metals has a
slight stabilizing effect on the active form of PAI-1 but
provides no additional stabilizing effect on the t1/2 of
PAI-1 when it is bound to vitronectin. Metals grouped
as Type II include cobalt, nickel, and copper. Each of
the Type II metals invokes a destabilizing effect on
PAI-1 and also shows a marked stabilizing effect on
the t1/2 of the PAI-1/vitronectin complex. Thus, the
Type II metals confer a vitronectin-dependent modu-
lation of PAI-1 stability. Nickel shows the largest
modulation, with a 40-fold difference in the t1/2
observed in the absence and presence of vitronectin.
The t1/2 of the complex with copper is six times longer
than that observed for isolated PAI-1 with copper, and
it is two times longer than the PAI-1/vitronectin
control with sodium chloride added. In some cases,
metals have been shown to induce protein aggrega-
tion.31–34 To determine whether the unusual effects of
metals on PAI-1 activity were simply the result of
protein oligomerization, sedimentation velocity
experiments using analytical ultracentrifugation
were performed. From this analysis (data not shown),
PAI-1 was observed to remain monomeric in the pres-
ence of added metals.
To complement the kinetic assay, direct visual-
ization of various species formed upon mixing of
PAI-1 with tPA was accomplished via a series of gel
experiments to ensure that the loss of tPA inhibition
measured in the kinetic assay using chromogenic
substrate reflects the conversion of PAI-1 to the
latent conformation. As shown in the scheme in Fig-
ure 3(a), PAI-1 and the protease bind and form an
initial noncovalent complex, and attack of the prote-
ase on the serpin in the RCL gives a transient cova-
lent intermediate (P--tPA), which is rapidly con-
verted to the inactive acyl-enzyme (P—tPA) via a
large conformational rearrangement. In some cases,
water attacks the transient intermediate before the
conformational change occurs, and the protease dis-
sociates from the complex leaving cleaved PAI-1
(PC). As PAI-1 converts to the latent form (PL) over
time, it cannot bind the protease and proceed along
this pathway.
The various species in this reaction scheme (P—
tPA, PL, and PC) are detected in SDS gels, and Fig-
ure 3(b,c) illustrate the relative amounts of these
products that form over the 60-min time period in
the presence of the various metals. When assayed
immediately after the addition of any metal to PAI-
1, the serpin forms significant amounts of 1:1 com-
plex [P—tPA, Fig. 3(b)]; however, the presence of
Type II metals, especially copper, induces a confor-
mation of PAI-1 that gives more substrate form [PC,
Table I. Metal Effects on the Stability of PAI-1 in the Presence and Absence of Vitronectin
Additivea VN klat (s
1) t1/2 (h) Fold stabilization with VN
None  1.69 (6 0.04)  104 1.14 (6 0.03)
þ 1.27 (6 0.02)  104 1.51 (6 0.03) 1.33 (6 0.04)
NaCl  1.71 (6 0.05)  104 1.12 (6 0.03)
þ 1.11 (6 0.04)  104 1.73 (6 0.05) 1.54 (6 0.06)
MgCl2  1.45 (6 0.04)  104 1.33 (6 0.04)b
þ 1.14 (6 0.02)  104 1.69 (6 0.03) 1.35 (6 0.04)
CaCl2  1.55 (6 0.06)  104 1.24 (6 0.05)b
þ 1.17 (6 0.02)  104 1.64 (6 0.03) 1.32 (6 0.03)
MnCl2  1.58 (6 0.01)  104 1.22 (6 0.01)b
þ 1.04 (6 0.02)  104 1.85 (6 0.03) 1.52 (6 0.03)
CoCl2  13.9 (6 0.1)  104 0.138 (6 0.001)b
þ 0.63 (6 0.02)  104 3.0 (6 0.1)c 22.0 (6 0.9)
NiCl2  20 (6 1)  104 0.095 (6 0.07)b
þ 0.497 (6 0.004)  104 3.87 (6 0.03)c 40.8 (6 3.0)
a Metals were included at a 5 mM concentration.
b Significantly different from associated PAI-1 chloride control (P < 0.05).
c Significantly different from associated PAI-1 þ VN chloride control (P < 0.05).
Table II. Copper Effects on the Stability of PAI-1 in the Presence of the VN and SMB Domain
Additive Cofactor klat (s
1) t1/2 (h) Fold stabilization
NaCl None 2.28 (6 0.08)  104 0.85 (6 0.03) NA
VN 1.33 (6 0.04)  104 1.45 (6 0.04) 1.71 (6 0.08)
SMB 1.18 (6 0.03)  104 1.64 (6 0.04) 1.94 (6 0.08)
CuCl2 None 3.77 (6 0.14)  104 0.51 (6 0.02)a NA
VN 0.63 (6 0.06)  104 3.08 (6 0.27)b 6.03 (6 0.58)
SMB 0.74 (6 0.05)  104 2.62 (6 0.17)c 5.13 (6 0.39)
a Significantly different from PAI-1 chloride control (P < 0.05).
b Significantly different from PAI-1 þ VN chloride control (P < 0.05).
c Significantly different from PAI-1 þ SMB chloride control (P < 0.05).
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Fig. 3(b)]. This correlation extends to experiments
using metals with PAI-1 in the presence of vitronec-
tin [Fig. 3(c)]. After incubation for 60 min at 37C,
PAI-1 mixed with Type I metals retains some activ-
ity, as indicated by the presence of the 1:1 complex
and/or cleavage of PAI-1 as a substrate for the prote-
ase [Fig. 3(b)]. In contrast, PAI-1 mixed with Type II
metals is essentially completely converted to the
unreactive latent form (PL) within the same time
frame [Fig. 3(b)]. This trend, in which there is a
large increase in the amount of latent PAI-1
observed at 1 h when the Type II metals are present,
agrees with the destabilization observed in the
steady state kinetic assay. In the presence of vitro-
nectin, these results with Type II metals are
reversed so that PAI-1 is stabilized and more com-
plex persists at the 60-min time point [Fig. 3(c)].
However, after the 1-h incubation at 37C, PAI-1
mixed with the Type I metals and vitronectin exhib-
its significantly more latent form than PAI-1 mixed
with any of the Type II metals and vitronectin [Fig.
3(c)]. These results are consistent with the demon-
stration from the kinetic assays that the Type II
metals confer a vitronectin-dependent stabilization
on PAI-1.
From these analyses, the increase in the rate of
loss of PAI-1 upon addition of the Type II metals
appears to occur at the same time that the latent
form of the protein increases in the reaction mix-
ture. What is not obvious from these studies is
whether there is oxidation of PAI-1 that occurs upon
addition of these metals that is responsible for the
loss of activity. Although the possibility of oxidative
damage cannot be ruled out from these experiments,
it is considered unlikely from the results with added
metals and vitronectin. In the case of PAI-1 in the
presence of the Type II metals and vitronectin, there
is a substantial stabilization of the protein so that it
Figure 3. SDS-PAGE gel showing vitronectin/metal modulation of reaction products formed upon inhibition of sc-tPA by PAI-
1. Panel A is a reaction scheme showing the fates of PAI-1 before and after its reaction with tPA, where PA is active PAI-1, PL
is latent PAI-1, PtPA is the Michaelis complex, P--tPA is the transient covalent intermediate, P—tPA is the stable complex in
which tPA has been captured, and PC is the cleaved form of PAI-1 in which hydrolysis of the transient complex is
accomplished. PAI-1 alone (Panel B) or PAI-1 plus vitronectin (Panel C) were mixed with the given metal chloride and then
incubated at 37C for the time shown (0 min or 60 min). Samples were mixed with excess sc-tPA and then run under
reducing conditions on 4–12% gradient SDS-PAGE.
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retains activity for a longer period of time. This
would not be expected if the protein incurred oxida-
tive damage from addition of the metals.
Metal effects on PAI-1 stability when complexed
with the SMB domain are comparable to effects
of full-length vitronectin
A considerable body of work recently published by
our group35–37 has established a more extensive
binding interface between vitronectin and PAI-1
than had previously been recognized. These studies
have shown that binding sites exist in addition to
the well-characterized interactions between PAI-1
the N-terminal SMB domain of vitronectin.35–37
Therefore, we were interested to see whether the
same dramatic effects on metal modulation of PAI-1
stability observed with full-length vitronectin were
exhibited by the SMB domain. Furthermore, the
comparison of data for the SMB domain vs. intact vi-
tronectin was useful to ascertain whether some of
these observed effects are caused by a vitronectin/
metal interaction in addition to a PAI-1/metal inter-
action. For these reasons, the stability of the PAI-1/
SMB domain complex was compared in the presence
of metals using the SDS-PAGE method and the ki-
netic assay.
Kinetics of PAI-1 inactivation were measured
using copper to evaluate the rate of conversion of
PAI-1 to the latent form with and without the SMB
domain. As is the case in the presence of full-length
vitronectin, the data for the rate of conversion of the
active form to the latent conformation of PAI-1 fit
well to a single exponential equation [Fig. 4(a)] and
resulted in klat values and half-lives similar to the
corresponding values with full-length vitronectin
[Table II and Fig. 4(b)]. Nonetheless, some differen-
ces are worthy of note. First, the SMB domain con-
fers a modestly greater stabilization of active PAI-1
compared to full-length vitronectin. Second, the PAI-
1/SMB complex in the presence of CuCl2 is some-
what less stable than the PAI-1/vitronectin complex
in the presence of CuCl2. These differences are con-
sistent with a relatively minor contribution from the
more extensive PAI-1/vitronectin interaction surface
that extends beyond the sequence encompassed by
the SMB domain.35–37 Aside from these nuances,
data on the complexes with the SMB domain largely
recapitulate the metal effects on PAI-1 observed
with full-length vitronectin. These findings indicate
that the majority of the stabilizing effect of vitronec-
tin results from the intermolecular interactions with
PAI-1 via the high-affinity binding site in the SMB
domain. The fact that similar metal effects on PAI-1
stability are observed with vitronectin and the much
smaller SMB domain suggests that metal effects are
largely accounted for by binding to PAI-1, and it is
less likely that vitronectin/metal interactions con-
tribute to a great extent to the observed effects.
The kinetic assay with PAI-1 and the SMB do-
main was accompanied by an analysis of reaction
products in gels with inclusion of various metals
(Fig. 5). From the results of mixing tPA and PAI-1
with the series of metals in the absence or presence
of the SMB domain [Figs. 5(a) and 5(b), respec-
tively], it is apparent that the SMB domain gives
similar results as those observed with intact vitro-
nectin [Fig. 3(c)]. In summary, PAI-1 forms a 1:1
complex with tPA to a similar extent with the SMB
domain compared to full-length vitronectin for all of
the metals tested [compare Figs. 3(c) and 5(b)]. This
is observed at both the 0- and 60-min time points.
PAI-1 mixed with Type I metals is stabilized over
time to a similar, modest extent in the presence of
the SMB domain. Again, most striking are the dif-
ferences with the Type II metals, where the conver-
sion to the latent conformation is dramatically influ-
enced by the presence of vitronectin or the SMB
Figure 4. Kinetic assay evaluating the SMB domain in
modulating metal effects on PAI-1 stability. Panel A is semi-
log plot showing a single exponential fit to the loss of PAI-1
activity in the presence of the SMB domain and CuCl2,
compared to PAI-1 in the presence of the SMB domain
with only NaCl added. Panel B is a comparison of the t1/2
for PAI-1 with or without vitronectin in the presence of NaCl
or CuCl2 (data from Table II) and PAI-1 with or without the
SMB domain in the presence of NaCl or CuCl2 (data from
Table II). All kinetic data represent the mean and standard
error for three separate experiments.
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domain. PAI-1 mixed with Type II metals is essen-
tially completely converted to the unreactive latent
form (PL) by 60 min without the SMB domain. With
Type II metals and the SMB domain, as observed
with full-length vitronectin, the opposite is observed
so that PAI-1 is stabilized over the same time frame,
and there is a notable reduction in the amount of
latent PAI-1 observed on gels at the 1-h time point.
These results agree with the stabilization by the
SMB domain observed in the kinetic assay.
The results using the SDS-PAGE assay, as
quantified in Figures 3 and 5(c,d), offer a more
direct comparison of reaction products after mixing
PAI-1 and tPA at 0- and 60 min. Figure 5(c) shows
the relative amounts of the substrate form of PAI-1,
apparent as the cleaved product (PC), which is
formed immediately after mixing of PAI-1 with the
various metals. Gels run on samples at the 0-time
point reveal effects of metals on the conformation of
PAI-1 that are not apparent from the solution ki-
netic assays using chromogenic substrates. From
this analysis, it is apparent that the Type II transi-
tion metals favor partitioning of the reaction path-
way so that more of the substrate conformation
Figure 5. SDS-PAGE analysis of the effects of the SMB domain compared to full-length vitronectin in modulating the
inhibition of tPA by PAI-1 in the presence of metals. PAI-1 alone (Panel A) or PAI-1 plus the SMB domain (Panel B) were
mixed with the given metal chloride and then incubated at 37C for the time shown (0 min or 60 min). Samples were mixed
with excess sc-tPA and then run under reducing conditions on 4–12% gradient SDS-PAGE. In Panel C, the amount of
cleaved band [PC, Fig. 3(a)] seen at the 0 min-time point for each condition was quantified and then normalized relative to
that for PAI-1 with NaCl (see methods). In Panel D, the latent band [PL, Fig. 3(a)] at the 0-min time and 60-min time points
was quantified and then the 0-min time point was divided by the 60-min time point to give the fold increase (see Methods).
For Panels C and D, measurements are plotted for PAI-1 alone (blue bars), PAI-1 plus vitronectin (magenta bars), and PAI-1
plus the SMB domain (green bars). The data for PAI-1 plus vitronectin used in these gel assays are shown in Figure 3(b). All
values shown in Panels C and D represent the average of measurements from three separate gels with error bars showing
the standard deviation.
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forms, regardless of whether vitronectin or the SMB
domain is present.
Figure 5(d) documents the accumulation of
latent PAI-1 at the 1 h time point relative to the
amount initially present in the reaction mixture for
all metals in the absence and presence of full-length
vitronectin or the SMB domain. With Type I metals,
the relative amount of latent PAI-1 at 60 min
increases as expected over time and is essentially
the same with either the SMB domain or vitronectin
present. The amount of latent PAI-1 also increases
at 60 min, without added vitronectin or the SMB do-
main with Type I metals. Although the absolute
amounts of PL at 1 h are fairly comparable under all
three conditions, the amounts of PL with vitronectin
or the SMB domain are increased in a relative sense
because there is less PL at the 0-time point with
Type I metals and vitronectin or the SMB domain.
Once again, most striking in Figure 5(d) are the
effects of Type II metals, where the difference
between the relative amount of PL that accumulates
in 60 min is markedly reduced in the presence of the
SMB domain or vitronectin, as observed in the solu-
tion kinetic assays. There are some minor differen-
ces in the relative amounts of cleaved [Fig. 5(c)] and
latent PAI-1 [Fig. 5(d)] that form in the presence of
the Type II metals comparing the SMB domain and
vitronectin. Such observations parallel differences
comparing the SMB domain and full-length vitronec-
tin observed with the solution-based kinetic assays.
For example, in the presence of cobalt, more of the
cleaved form of PAI-1 is detected with vitronectin
than with the SMB domain [Fig. 5(c)]. Overall the
gels substantiate what is observed in the solution-
based kinetics and provide additional details regard-
ing effects of metals on PAI-1 structure. These
opposing effects of Type I and Type II metals on
PAI-1 conformation are further evaluated in the
companion paper.38
Discussion
This work provides the first evidence for distinct
effects of metals on the structure and function of
PAI-1. Profound consequences of metal binding are
invoked on the structural transition of PAI-1 from
the active to latent conformation, and the effects of
vitronectin as a cofactor that stabilizes PAI-1 are de-
pendent on the presence of metals. Metals have two
kinds of effects on PAI-1. Type I metals invoke a 10–
20% increase in the stability of PAI-1, so that the
conversion of the active to latent conformation
occurs more slowly. Type I metals have no apparent
enhancement of PAI-1 half-life when it is complexed
with vitronectin. More substantial effects are
observed with the Type II metals, where marked
destabilization of PAI-1 occurs and the conversion to
the latent conformation occurs within minutes. In
these cases, vitronectin reverses the situation so
that the PAI-1/vitronectin complexes in the presence
of Type II metals are stabilized to a much greater
extent than is observed in the absence of added
metal.
What properties characterize Type I and II
metals?
Metal binding to proteins is a function of size, polar-
izability, and hybridization geometry. These consid-
erations of the physical and chemical properties of
metals have been considered a biological context
using a survey of X-ray structures.39 From this anal-
ysis, classes of metal-binding sites in proteins were
categorized according to whether the metals are oxy-
gen-seeking versus nitrogen/sulfur seeking. Oxygen
is smaller and less polarizable than nitrogen or sul-
fur.39 Such class designations describe the tendency
of a metal/ligand complex to have either ionic bond
(class A) or partially covalent bond (class B) charac-
ter.39 The Type I metals Ca2þ and Mg2þ are both
class A, whereas Mn2þ is in the Borderline class
between A and B. The Type II metals Ni2þ, Co2þ,
and Cu2þ also are all within the Borderline category,
but they tend to be more class B-like.39 Also,
although a single metal often exhibits various geo-
metries, each has preferred coordination states. For
magnesium and manganese, the geometry tends to
be octahedral. In contrast, the coordination geometry
of the Type II metals is almost always tetrahedral.
In the case of IMAC, the metal ligand is bound by
functional groups both on the column resin and the
protein; however, an intrinsic metal-binding site
with a full complement of coordinating centers
appears to be present within PAI-1. It is thus
unclear whether residues contributing to binding in
IMAC also comprise the intrinsic metal-binding site.
Differences in polarizability of the two types of met-
als, their oxygen-seeking or nitrogen-seeking proper-
ties, and their coordination geometries suggest that
two different metal binding sites could exist in PAI-
1. It should be noted, however, that there are cases
in which a single metal-binding site on a protein can
accommodate different geometries and can provide
different side-chain or backbone atoms to accommo-
date different metals at the same site. For example,
crystallographic databases show that magnesium
and manganese can bind to the same site, although
manganese can tolerate nitrogen ligands better than
magnesium.40 The question of whether there are two
physically distinct metal-binding sites on PAI-1, or a
common site with multiple binding modes must
await further study and is addressed in part in the
companion study.38
What are biological roles for metals and PAI-1?
The role of metals in biology is an intensively stud-
ied area that spans across all domains of life. Ele-
gant systems for metal homeostasis have developed
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because of the need to regulate appropriate bioavail-
able metal stores and to avoid the harmful oxidative
effects that can arise at elevated concentrations.
Work over the years has demonstrated a role for
metals in the severity of the inflammatory response,
tumor progression, diabetes, atherosclerosis, and
neurological disease. In each of these pathologies,
PAI-1 and/or vitronectin have been implicated. Inter-
estingly, the most prominent impacts of vitronectin
on stabilizing PAI-1 occur with metals that have
growing importance in a broad range of physiological
settings.41–43
A relevant interaction in vivo must be defined
by a binding affinity that falls within a physiological
range in terms of metal bioavailability. Thus,
depending on local concentrations and affinities,
these metals may play key roles in modulating the
regulatory role of PAI-1 and its cofactor, vitronectin.
Because this venture into metal effects on PAI-1 was
unprecedented so that affinities were not known,
high concentrations of metal were used in these ki-
netic protocols to ensure saturation conditions.
Although the levels in the kinetic assays exceed
physiologically relevant metal concentrations,44 the
concentration of free metal is substantially less than
the total of 5 mM used due to significant metal:-
buffer interactions. For example, the free concentra-
tion in these assays using copper, the transition
metal that is the most relevant for physiology as the
third most abundant trace metal in the body, is
likely less than 4 lM. A companion study was pur-
sued with the goal of measuring the affinity of PAI-1
for metals and characterizing mechanistic aspects of
conformational changes and metal binding.38 This
additional work shows that PAI-1 affinity for these
metals corresponds to concentrations of bioavailable
metal stores in vivo.
Do metals affect the conformation of PAI-1 to
adopt varied biological roles?
With the understanding about PAI-1 structure that
has come from structural studies using X-ray crys-
tallography has come an appreciation of conforma-
tional transitions in its mechanism for inactivating
proteases.11,27,30,45–48 Changes in serpin conforma-
tion that occur upon targeting proteases, binding
and entrapment via a long-lived acyl intermediate
have been intensely studied.49–51 In particular,
investigations into serpins of all kinds, including
antithrombin-III (the main inhibitor of coagulation
proteases) and the prototype in the family, anti-tryp-
sin, have focused on the way in which RCL flexibil-
ity drives the conformational transitions key to this
elegant mechanism.52–58 Clearly, metals have a
direct affect on RCL conformation, as the Type II
transition metals promote the conversion of active
PAI-1 to its latent conformation via RCL rearrange-
ment. Interestingly, vitronectin tempers this confor-
mational relaxation in PAI-1 so that the RCL is
maintained in its surface exposed and active orienta-
tion for a much longer period of time.
In addition to its role in stabilizing PAI-1, an im-
portant role for vitronectin appears to be localizing
PAI-1 to the site where it is needed. Consistently, we
have shown that PAI-1 is targeted to the fibrin matrix
of blood clots exclusively via vitronectin.59 In addition
to maintaining the delicate balance required between
coagulation and thrombolysis, PAI-1 regulates the
plasminogen activation system when it operates in
pericellular proteolysis that affects tissue remodeling,
wound healing, and cancer progression. As such,
immunological approaches have identified vitronectin
as the major PAI-1-binding protein in the ECM of cul-
tured endothelial cells.60 The co-localization of the
two proteins in vivo is well documented.61–65 Appro-
priate control of PAI-1 function is vital not only to
hemostasis but also for regulation of many activities
in tissues, including inflammation, neurological activ-
ity, angiogenesis, and tumor growth.66–68 The ability
of metals to modulate PAI-1 activity and conformation
reveals a mechanism by which PAI-1 may be regu-




PAI-1 cloned into the expression vector pET 24d and
the PAI-1 14-1b mutant20 were a gift from Grant
Blouse, Henry Ford Health Sciences Center Detroit,
MI. Single chain (sc-tPA), two chain tPA (tc-tPA), and
the mouse antihuman vitronectin 1E934 antibody were
purchased from Molecular Innovations Inc. Novi, MI.
Spectrozyme tPA was purchased from American Diag-
nostics Inc. Stamford, CT. Protease inhibitor cocktail
P8465 was purchased from Sigma Aldrich Corp. St.
Louis, MO. SP Sepharose Fast Flow FF, chelating
Sepharose FF, DEAE Sephacel, blue Sepharose, hepa-
rin Sepharose, high-resolution Sephacryl S100/S200,
and NHS-activated Sepharose FF were purchased from
GE Healthcare Piscataway, NJ. The Pierce BCA assay
kit was purchased from Thermo Scientific Rockford, IL.
Rosetta2(DE3)pLysS and Rosetta-Gami2(DE3)pLysS
competent cells, the pET 32b expression vector, and
restriction grade thrombin were purchased from EMD
Biosciences Gibbstown, NJ. The cloning vector pCR2.1
was purchased from Invitrogen Inc Carlsbad, CA. The
QuikChange XL II kit for mutagenesis was purchased
from Stratagene Inc Cedar Creek, TX. All other
reagents were of analytical grade and used without fur-
ther purification.
PAI-1 expression and purification
Expression of recombinant PAI-1 used the pET24d
vector containing PAI-1 in the E. coli
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Rosetta2(DE3)pLysS strain grown in TB media con-
taining 50 lg/mL kanamycin and 34 lg/mL chloram-
phenicol. Expression of PAI-1 was induced by adding
1 mM IPTG, and PAI-1 was purified using ion
exchange on SP-Sepharose, IMAC on nickel charged
resin, and gel filtration on Sephacryl S-100 resin. Pro-
tein identity was confirmed by western blot and
MALDI-MS. PAI-1 concentration was determined at
280 nm using e280 ¼ 0.93 mL mg1 cm1,69 and a mo-
lecular weight ¼ 43760 g/mol.
Chromatography of PAI-1 14-1b using
immobilized transition metals for IMAC
Lysates of E. coli overexpressing the stable 14-1b
mutant form of PAI-130 were passed over 1 mL
HiTrapTM chelating HP columns charged with Ni2þ,
Co2þ, Cu2þ, Zn2þ, or Mn2þ, washed with 50 mM
NaH2PO4 and 100 mM NaCl pH 6.6, and then eluted
with a 10 column volume linear imidazole gradient.
Preparation of human vitronectin proteins
Vitronectin was purified from 3 L of fresh frozen
human plasma as described previously70–72 with
minor modifications. Vitronectin concentration was
determined at 280 nm using e280 ¼ 1.0 mL mg1
cm1,73 and a molecular weight ¼ 62,000 g/mol.74
The sequence encoding the first 47 amino acids of vi-
tronectin (the SMB domain and the RGD sequence)
was cloned into the pET32b vector as a thioredoxin
fusion protein using standard protocols for PCR
amplification and subcloning. The Stratagene Quik-
Change VR XL II protocol was used to introduce the
stop codon within the coding sequence for vitronec-
tin and also to change the enterokinase cleavage site
on the pET32b vector to a thrombin cleavage site.
The resulting plasmid was transformed into Rosetta-
gami 2(DE3)pLysS cells and selected by growth on
LB agar containing 50 lg/mL ampicilin, 34 lg/mL
chloramphenicol, and 12.5 lg/mL tetracycline. Cells
were resuspended in 50 mM NaH2PO4, 500 mM
NaCl, and 20 mM imidazole pH 7.0 and lysed by
sonication in an ice bath. Cell debris was removed
via centrifugation. The lysate was loaded onto a
nickel Sepharose FF column, and proteins were
eluted with a 20–500 mM imidazole gradient. Frac-
tions containing the thioredoxin-SMB fusion protein
were pooled and dialyzed against 20 mM Tris, 150
mM NaCl, and 2.5 mM CaCl2. A total of 15 U of
thrombin was added to 400 mg of fusion protein
and incubated with shaking at room temperature
overnight. After cleavage, the N-terminus of this
recombinant SMB domain construct has the four
amino acid extension: GSAM. The protein was again
passed over the nickel column, and the flow through
was captured, concentrated, and chromatographed
on a 580 mL S-100 gel filtration column equilibrated
in 50 mM NaH2PO4, 300 mM NaCl, and 1 mM
EDTA.
Correctly folded SMB domain was isolated from
the mixture via affinity chromatography on a col-
umn coupled with the 14-1b mutant of PAI-1, an
inherently stable form of PAI-1 that contains four
mutations that prevent it from converting to the
latent form.30 Aliquots of the SMB domain purified
by S-100 chromatography were added to the affinity
column, followed by washing with 50 mM NaH2PO4,
300 mM NaCl, and 1 mM EDTA pH 7.4. Bound
SMB domain was eluted from the affinity column
with the same buffer at pH 4.0. RP-HPLC showed
one peak for the affinity purified SMB domain, and
protein identity was confirmed by MALDI-MS. Ac-
tivity was established by an assay that used surface
plasmon resonance (SPR). In this assay, using a mix-
ture of the SMB domain and PAI-1 at 1:1 stoichiom-
etry (25 nM:25 nM), the SMB domain gave complete
inhibition of PAI-1 binding to a vitronectin-coated
SPR chip. The SMB domain concentration was
determined at 276 nm using e276 ¼ 4500 M1
cm1,75 and a molecular weight ¼ 5678.26 g/mol
(calculated from the amino acid sequence including
four disulfide bonds).
PAI-1 anti-protease activity assay
The inhibitory activity of the PAI-1 preparation was
tested by titration with tc-tPA. The relative amount
of functional tPA was determined using a chromo-
genic assay by addition of 1 mM Spectrozyme tPA.13
The release of free p-nitroaniline upon cleavage of
the substrate by tPA was monitored at 405 nM. PAI-
1 showed complete inhibition of tPA function
between 1.0 and 1.25 equivalents, consistent with
essentially fully active inhibitor. The activity of
PAI-1 was routinely checked by SDS-PAGE to mea-
sure complexed, cleaved, or latent PAI-1 form upon
addition of either tPA or uPA. From these analyses
(described in detail below), it was observed that typi-
cal PAI-1 preparations were 85% active, consistent
with the chromogenic assays.
PAI-1 stability assay
The rate of conversion of PAI-1 to the latent form
was determined as previously described13 with the
following alterations. A sample of 100 nM PAI-1 in
the absence of presence of 150 nM human vitronec-
tin or the SMB domain was equilibrated in 100 mM
Tris-HCl, 1% BSA, and 1 mM EDTA pH 7.4 at 37C.
Metal chloride was added to a final concentration of
5 mM metal and 10 mM chloride. In the case of
NaCl, final concentrations were 10 mM sodium and
chloride. Over time, aliquots were mixed with tc-tPA
at a final concentration of 50 nM PAI-1 and 60 nM
tPA. The relative amount of active PAI-1 was deter-
mined by its ability to inhibit functional tPA using 1
mM Spectrozyme tPA as a substrate and monitoring
the release of p-nitroaniline by absorbance at 405
nM. Relative PAI-1 activity was normalized and fit
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to a single exponential to determine klat, the rate
constant for conversion to the latent form. Data
were collected for 10 PAI-1 half-lives. All data are
the average of three separate experiments.
Experiments in the presence of copper required
alterations to the above protocol. BSA was excluded
from the buffer to avoid copper (I) formation via the
Biuret reaction. Control experiments were repeated
in the absence of BSA for comparison. Also, the ini-
tial copper solution (10 mL of 10 mM CuCl2) was
titrated with 35 lL of 6M NaOH (20 mM total) to
restore the pH to 7.4.
The formation of the tPA/PAI-1 complex, as well
as unreactive/latent and cleaved PAI-1 in the pres-
ence or absence of metals, was visualized by reduc-
ing SDS-PAGE. Because of overlapping migration of
BSA with vitronectin in the gels, BSA was excluded
from the buffer; the final buffer components were
100 mM Tris-HCl and 1 mM EDTA pH 7.4 at 37C.
A concentrated metal stock was added to a sample of
PAI-1 alone, PAI-1 mixed with human vitronectin or
PAI-1 mixed with the SMB domain, in a final vol-
ume of 55 lL and final concentration of 5 mM metal
chloride (10 mM NaCl), 4 lM PAI-1, and 6 lM vitro-
nectin or SMB. The sample was then either mixed
immediately with excess sc-tPA (i.e. 6.6 lL of 47 lM)
or incubated at 37C for 60 min and then mixed
with the sc-tPA. Note that single chain tPA was used
in the gel assays, in spite of its relatively lower ac-
tivity compared to two-chain tPA, because the single
chain form is more easily separated from vitronectin
compared to tc-tPA in SDS-PAGE. After protease
addition, the samples were incubated for 10 min at
room temperature, and the reaction was stopped by
the addition of 20 lL of reducing SDS-PAGE loading
dye. Samples were boiled for 5 min, and then 12 lL
was electrophoresed on a 4–12% gradient gel.
Gel bands for the cleaved and latent forms of
PAI-1 were quantified using Bio-Rad Quantity
OneTM software with digital images of gels recorded
on a Biorad ChemiDoc XRS photodocumentation sys-
tem. Visible bands and a region corresponding to the
gel background were delineated using the selection
tool. The software was used to normalize the inten-
sity of the bands relative to the intensity of the
selected background, yielding the adjusted-intensity-
volume. Results from quantification of the cleaved
band at the 0-min time point were normalized based
on a value of 1 for the control with PAI-1 and NaCl.
Data from the latent PAI-1 band at both 0-min and
60-min time points were analyzed to determine a
relative increase over this time period by dividing
the adjusted-intensity-volume measurements for the
0-min time point by that for the 60-min time point.
Only cleaved and latent bands were analyzed
because it was not possible to quantify directly the
amount of PAI-1-tPA complex with this approach
due to the diffuse migration of this species on SDS-
PAGE. This is due to the heterogeneity of tPA result-
ing from variable glycosylation, which also is appa-
rent for the migration of the isolated sc-tPA protein
in the electrophoretic field. Therefore, to establish
the amount of active PAI-1 in a given sample, the
amount of cleaved and unreacted/latent bands on
the gel upon the reaction with tPA was determined
by densitometry and compared to the amount of
PAI-1 in a control sample on the same gel without
tPA. The difference in the total amount of PAI-1
detected as unreacted or cleaved protein comparing
the sample þ/ tPA was attributed to the amount of
active PAI-1 that formed a complex with tPA. This
amount was typically 85% of the total.
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